Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS 449884
- Development stage
- Phase 2
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous Injection[1][8]
01
Overview
ISIS 449884 is a 2'-O-methoxyethyl (2'-MOE) antisense oligonucleotide that targets the glucagon receptor (GCGR). By binding to the mRNA of the glucagon receptor in liver and adipose tissue, it reduces GCGR expression and thereby inhibits glucagon signaling. This leads to reduced hepatic glucose output and lower blood glucose levels. The drug has been studied as both monotherapy and as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM), showing significant reductions in HbA1c compared to placebo without increased risk of hypoglycemia. It represents a novel mechanism among antidiabetic agents by directly targeting glucagon action at the receptor level[1][5][7].
- Other names
- IONIS GCGRRxISIS-449884 sodiumISIS449884 sodiumISIS 449884 sodium
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on ISIS 449884.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS 449884.